Evidence map›Paper›PMID 39928161›Full record

ArticleJournal of cancer research and clinical oncology2025

Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin.

John S Wang, Jack C Shapiro, Sarah Orlando, Rusul Al-Marayaty, Farres Obeidin, David VanderWeele, Haris Charalambous, Seth M Pollack, Pedro Hermida de Viveiros

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

John S WangFeinberg School of Medicine, Department of Medicine, Division of Oncology, Northwestern University, Chicago, IL, USA. john.wang@nm.org.
Jack C ShapiroFeinberg School of Medicine, Department of Medicine, Division of Oncology, Northwestern University, Chicago, IL, USA.
Sarah OrlandoUniversità Campus Bio-Medico di Roma, Rome, Italy.
Rusul Al-MarayatyMedStar Health/Georgetown-Washington Hospital Center, Washington, DC, USA.
Farres ObeidinFeinberg School of Medicine, Department of Pathology, Northwestern University, Chicago, IL, USA.
David VanderWeeleFeinberg School of Medicine, Department of Medicine, Division of Oncology, Northwestern University, Chicago, IL, USA.
Haris CharalambousBank of Cyprus Oncology Center, Nicosia, Cyprus.
Seth M PollackFeinberg School of Medicine, Department of Medicine, Division of Oncology, Northwestern University, Chicago, IL, USA.
Pedro Hermida de ViveirosFeinberg School of Medicine, Department of Medicine, Division of Oncology, Northwestern University, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDesmoplastic small round cell tumor is a rare sarcoma type with poor prognosis for which there is no standard of care. It primarily affects adolescents and young adults and treatment is both multimodal and challenging due to the aggressive nature of the disease. CASE PRESENTATION: we describe a case of a 27-year-old male who presented with hematuria and a five-centimeter mass on his bladder wall. His case details an especially challenging diagnosis as the pathology and IHC raised the suspicion for a poorly differentiated urothelial carcinoma until next-generation sequencing revealed the ESWR1::WT1 fusion gene rearrangement pathognomonic for desmoplastic small round cell tumor. After failing multiple lines of chemotherapy and also pembrolizumab, the patient was started on enfortumab-vedotin (EV), an antibody-drug conjugate targeting Nectin-4. Patient sustained partial response and documented disease control with clinical benefit for 23 months. Later, IHC staining of the tumor for nectin-4 was found to be moderately positive.

conclusionThis case report is the first documented usage of EV in the management of a desmoplastic small round cell tumor case and gives light to a new potential therapeutic strategy for this rare and aggressive tumor.

Indexed as

Antibodies, MonoclonalDesmoplastic Small Round Cell TumorUrinary Bladder NeoplasmsAdultCell Adhesion MoleculesHumansMaleNectinsAntibodies, MonoclonalCell Adhesion Moleculesenfortumab vedotinNECTIN4 protein, humanNectinsImmunohistochemistryNext Generation SequencingSarcomaTargeted Therapy

Identifiers

PMID39928161
PMCPMC11811468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.